Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 3-Methylbutanoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.88 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Methylbutanoic Acid SCHEMBL29461587 | 0.97 | CA2 (0.94) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL3682595 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL3182324 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL8572469 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL8570885 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL8572668 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL8388209 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL9124487 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 | |
| 3-Methylbutanoic Acid SCHEMBL5462119 | 0.94 | — | — | |
| 3-Methylbutanoic Acid SCHEMBL9124489 | 0.94 | CA2 (0.88) | CA2CA1ALDH1A1TDP1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719357-A1 | COMPOSITIONS COMPRISING SOTORASIB | Amgen Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024249660-A1 | COMPOSITIONS COMPRISING SOTORASIB | AMGEN INC. (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240226020-A1 | SOTORASIB FORMULATION | AMGEN INC. | 2024-07-11 | — | — | US | claimed |
| EP-4333813-A1 | SOTORASIB FORMULATION | AMGEN INC. (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117222403-A | Soto-raschib formulation | 安进公司 | 2023-12-12 | — | — | CN | claimed |
| WO-2022235904-A1 | SOTORASIB FORMULATION | AMGEN INC. (US) | 2022-11-10 | — | — | WO | claimed |
| US-10945960-B2 | Celecoxib and amlodipine formulation and method of making the same | DEXCEL LTD. (IL) | 2021-03-16 | — | — | US | claimed |
| US-10925835-B2 | Celecoxib and amlodipine formulation and method of making the same | DEXCEL LTD. (IL) | 2021-02-23 | — | — | US | claimed |
| US-20200390713-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | PURPLE BIOTECH LTD (IL) | 2020-12-17 | — | — | US | claimed |
| US-20190282507-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | PURPLE BIOTECH LTD (IL) | 2019-09-19 | — | — | US | claimed |
| US-20190125792-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FERRIC CITRATE AND METHODS FOR THE PRODUCTION THEREOF | DEXCEL PHARMA TECHNOLOGIES LTD. (IL) | 2019-05-02 | — | — | US | claimed |
| WO-2019008583-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | DEXCEL LTD. (IL) | 2019-01-10 | — | — | WO | claimed |
| US-20190008777-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | PURPLE BIOTECH LTD (IL) | 2019-01-10 | — | — | US | claimed |
| EP-4719357-A1 | COMPOSITIONS COMPRISING SOTORASIB | Amgen Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249660-A1 | COMPOSITIONS COMPRISING SOTORASIB | AMGEN INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240226020-A1 | SOTORASIB FORMULATION | AMGEN INC. | 2024-07-11 | — | — | US | disclosed |
| US-4460701-A | COORDINATION CATALYSTS CONTAINING MAGNESIUM SALTS | TOHO TITANIUM CO., LTD. (JP) | 1984-07-17 | — | — | US | disclosed |
| US-4439537-A | Process for the preparation of catalyst component for the polymerization of olefins | TOHO TITANIUM CO., LTD. (JP) | 1984-03-27 | — | — | US | disclosed |
| EP-0085167-A1 | Alkoxylation with calcium and magnesium salts | Conoco Phillips Company (US) | 1983-08-10 | — | — | EP | disclosed |
| US-4104141-A | Electrochemical oxidation of alkoxy-substituted aromatic compounds | UOP INC. (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226020-A1 | SOTORASIB FORMULATION | BAK1, S1PR5, DSG1 | CA2 3583/4885CA1 3124/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.